Table I.
Patient characteristics.
| Case | Age (years) | Sex | Clinical stage | Site of metastasis | PS | Pre-protocol chemotherapy | Protocol DC (times) | Post-protocol DC (times) | Post-protocol chemotherapy | Outcome | OS (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 55 | M | IVb | Liver/para-aortic LN | 0 | 1st FP 2nd FP + RT | 4 | 5 | None | PD | 4.6 |
| 2 | 70 | M | Recurrence | Bone/para-aortic LN | 2 | 1st DCF (NAC : FP) | 4 | 0 | FP + RT | PD | 7.8 |
| 3 | 55 | M | Recurrence | Peritoneum/para-aorticLN | 1 | 1st FP | 4 | 3 | Ned + Doc | PD | 5.4 |
| 4 | 65 | M | Recurrence | PleuraLN/abdominal wall | 0 | 1st DCF (NAC : FP) | 4 | 1 | None | PD | 3.7 |
| 5 | 54 | M | Recurrence | Anastomosis site | 0 | 1st DCF (NAC : FP + RT) | 4 | 5 | None | PD | 5.3 |
| 6 | 61 | M | Recurrence | Lung/skin Mediastinum LN | 0 | 1st 5FU+CDDP+RT 2nd DCF 3rd PTX (NAC : FP) | 2 | 0 | None | PD | 1.9 |
| 7 | 49 | W | IVb | Lung/abdominal LN | 0 | 1st FP + RT 2nd PTX | 2 | 0 | None | SD | 1.1 |
| 8 | 73 | M | Recurrence | Lung | 1 | 1st FP + RT 2ndTS1 3rdDCF (NAC : FP) | 2 | 3 | None | PD | 11.6 |
| 9 | 71 | M | Recurrence | Mediastinum LN | 0 | 1st FP + RT 2nd DCF 3rd PTX (NAC : FP) | 6 | 0 | None | PD | 7.6 |
| 10 | 60 | M | Recurrence | Lung/mediastinum LN | 0 | 1st FP + RT 2nd Ned + DOC 3rd DCF 4th PTX (NAC : FP) | 2 | 0 | None | PD | 4 |
LN, Lymph node; PS, performance status; FP, 5-Fluorouracil and Cisplatin; RT, Radiotherapy; DCF, Docetaxel, Cisplatin, and 5-fluorouracil; NAC, Neo Adjuvant Chemotherapy; 5FU, 5-Fluorouracil; CDDP, Cisplatin; PTX, paclitaxel; Ned, nedaplatin; DOC, docetaxel, DC; dendritic cell; OS, overall survival.